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Ghrelin has protective and therapeutic effects in the gut. The aim of present studies was to investigate the effect of treatment with
ghrelin on the development of colitis evoked by dextran sodium sulfate (DSS).Methods. Studies have been performed on rats. Colitis
was induced by adding 5%DSS to the drinkingwater for 5 days.During this period animalswere treated intraperitoneally twice a day
with saline or ghrelin given at the dose of 8 nmol/kg/dose. On the sixth day, animals were anesthetized and the severity of colitis was
assessed. Results. Treatment with ghrelin during administration of DSS reduced the development of colitis. Morphological features
of colonic mucosa exhibited a reduction in the area and deep of mucosal damage. Ghrelin reversed the colitis-induced decrease in
blood flow, DNA synthesis, and superoxide dismutase activity in colonic mucosa. These effects were accompanied by a decrease
in the colitis-evoked increase in mucosal concentration of interleukin-1𝛽 and malondialdehyde. Treatment with ghrelin reversed
the DSS-induced reduction in body weight gain. Conclusions. Administration of ghrelin exhibits the preventive effect against the
development of DSS-induced colitis. This effect seems to be related to ghrelin’s anti-inflammatory and antioxidative properties.
1. Introduction
Crohn’s disease and ulcerative colitis are the two main forms
of inflammatory bowel disease (IBD) [1]. It is currently
suggested that IBD results from an abnormal immunological
response to micro flora present in the digestive system and its
pathogenesis is complex and requires coexistence of factors of
environmental and genetic nature [1–3]. There are numerous
methods to treat IBD, but medication that would ensure
permanent therapeutic effect has not been found so far [1,
3]. Therefore, it is vital to search for the new therapeutic
strategies.
Ghrelin was primary discovered in the human and rat
stomach by Kojima et al. [4]. The stomach is a major source
of circulating ghrelin [5], but it was also found in other
organs such as the bowel, pancreas, kidney, pituitary gland,
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and hypothalamus [6–8]. Ghrelin acts on a receptor pri-
marily known as the growth hormone secretagogue receptor
(GHS-R), which was currently renamed the ghrelin receptor
(GRLN-R) [9]. GRLN-R is mainly present in the pituitary
gland and hypothalamus, but it was also in other tissues of
the body [6, 9]. Ghrelin stimulates growth hormone secretion
[4] and body weight gain by an increase in food intake
and a decrease in utilization of fat tissue [9, 10]. Besides
these effects, ghrelin demonstrates anti-inflammatory and
therapeutic properties in different organs of the body. GRLN-
Rs are present, among others, in the immunological system
cells, suggesting that ghrelin may modulate inflammatory
response [11, 12].
In the gastrointestinal tract, administration of ghrelin
reduces gastric injury [13–15] and accelerates the healing of
gastric [16, 17], duodenal [16, 18], and oral ulcers [19] evoked
by different damaging agents. Pretreatment with ghrelin
inhibits the development of experimental acute pancreatitis
[20, 21] and its administration accelerates recovery in this
disease [22–24].
The role of ghrelin in IBD is not clear. Clinical studies
have shown that expression of mRNA for ghrelin is signif-
icantly upregulated in colonic mucosa in patients with IBD
and this effect is well-correlated with a grade of inflammation
[25, 26].
There are animal experimental studies concerning the
role of ghrelin in the development and healing of colitis. Some
studies have shown that administration of exogenous ghrelin
accelerates the healing of colitis evoked by trinitrobenzene
sulfonic acid (TNBS) in rats [25] and mice [27]. Therapeutic
effect of ghrelin has been also found in the course of dextran
sodium sulfate- (DSS-) induced colitis in rats [28]. In contrast
to those data are results obtained by De Smet et al. [29].
They have reported that endogenous and exogenous ghrelin
enhance the colonic manifestation of DSS-induced colitis in
mice. Proinflammatory properties of ghrelin in the colon
have been also postulated by Zhao et al. [30].They have found
that ghrelin stimulates interleukin-8 gene expression through
protein kinase C-mediated NF-kappaB pathway in human
colonic epithelial cells.
The objective of the present study was to determine the
influence of treatment with ghrelin on the development of
DSS-induced colitis in rats.
2. Materials and Methods
2.1. Animals and Treatment. The research was performed on
forty Wistar male rats weighing 180–250 g and conducted
following the experimental protocol approved by the First
Local Committee of Ethics for theCare andUse of Laboratory
Animals in Cracow. During the study, animals had free access
to food and fluids.
Animals were randomly divided into four groups: (1)
control rats without colitis treated intraperitoneally (i.p.) with
saline; (2) rats without colitis treated i.p. with ghrelin; (3)
rats treated i.p. with saline during induction of colitis; (4)
rats treated i.p. with ghrelin during induction of colitis. Each
experimental group consisted of 10 animals.
Colitis was induced by adding 5% DSS (40 kDa, Sigma-
Aldrich, St. Louis, USA) to the drinking water for 5 days
(groups 3 and 4).
Other animals had free access to tap water (groups 1 and
2). During this 5-day period, animals were treated i.p. twice a
day with saline (groups 1 and 3) or ghrelin (groups 2 and 4).
Rat ghrelin (Yanaihara Institute, Shizuoka, Japan) was given
at the dose of 8 nmol/kg/dose. This dose was chosen because
previous studies have shown that ghrelin given at the dose
8 nmol/kg/dose exhibits strong and repeatable therapeutic
effect in the healing of gastric, duodenal, and oral ulcers [16–
19].
On the sixth day, rats were anesthetized with ketamine
(50mg/kg i.p., Bioketan, Vetoquinol Biowet, Gorzo´w
Wielkopolski, Poland) and the severity of colitis was
assessed.
2.2. Measurement of the Body Weight Gain and Daily Water
Intake. In the study the effect of ghrelin and DSS on the
water intake and weight gain of the animals was identified.
Bodyweight of each animal was checked at the beginning and
after each day of study. Daily water intake was defined as the
difference between the initial volume of water and the volume
remaining in the water container before refilling.
2.3.Measurement of Colonic Blood Flood andMucosal Lesions.
Six days after induction of colitis, rats were anesthetized with
ketamine. After opening the abdominal cavity and exposing
the colon, the measurement of colonic blood flow volume
was performed using laser Doppler flowmeter (PeriFlux
4001 Master Monitor, Perimed AB, Ja¨rfa¨lla, Sweden), in
accordancewith themethodology described before [31]. After
measurement of colonic blood flow, the area of mucosal
damage was measured, using a computerized planimeter
(Morphomat, Carl Zeiss, Berlin, Germany) in accordance
with the method described earlier [31].
2.4. Biochemical Analysis. After measurement of colonic
blood flow and lesions area, biopsy samples of mucosa from
the colon were taken for determination of mucosal DNA
synthesis (an index of mucosal cell proliferation), concen-
tration of proinflammatory interleukin-1𝛽, concentration of
malondialdehyde (as an index of lipid peroxidation), and
activity of superoxide dismutase (SOD) (one of the endoge-
nous mechanisms for elimination of free oxygen radicals).
2.5. Determination of DNA Synthesis in Colonic Mucosa.
DNA synthesis was determined by measurement of
[3H]thymidine incorporation ([6-3H]- thymidine, 20–
30Ci/mmol, Institute for Research, Production and
Application of Radioisotopes, Prague, Czech Republic)
into mucosal DNA as described previously [32]. The
incorporation of labeled thymidine into DNA was
determined by counting 0.5mLDNA-containing supernatant
in a liquid scintillation system. The rate of DNA synthesis
was expressed as tritium disintegrations per minute per 𝜇g
of DNA (dpm/𝜇g DNA).
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2.6. Determination of Interleukin-1𝛽 Concentration in Colonic
Mucosa. Samples of colonic mucosa were homogenized in
ice-cold phosphate-buffered saline (PBS, 20mM, pH 7.4).
Homogenate was centrifuged at 1,500 g for 10min at 4∘C.
Content of interleukin-1𝛽 in the supernatant was measured
using the BioSource Cytoscreen rat IL-1𝛽 kit (BioSource
International, Camarillo, California, USA) based on ELISA.
Concentration of interleukin-1𝛽 in duodenal mucosa was
expressed as ng per g of tissue.
2.7. Determination of Malondialdehyde Concentration in
Colonic Mucosa. Peroxidation of lipids in colonic mucosa
was tested by measurement of malondialdehyde (MDA) con-
centration using commercial kit Bioxytech LPO-586 (Oxis-
Research,OXISHealth Products, Inc., Portland,OR,USA), as
described previously [33]. Mucosa was homogenized in ice-
cold Tris buffer (20mM, pH 7.4) and centrifuged (3000 g at
4∘C for 10min) and supernatant was used for the assay.
2.8. Determination of Superoxide Dismutase Activity in
Colonic Mucosa. To determine the activity of superoxide
dismutase (SOD) in colonicmucosa, tissue was homogenized
in 20mM HEPES buffer, pH 7.2, containing 1mM EGTA,
210mMmannitol, and sucrose. Homogenate was centrifuged
at 1,500 g for five min at 4∘C. Activity of SOD in the super-
natant was measured using Superoxide Dismutase Assay Kit
(Cayman Chemical Company, Ann Arbor, MI, USA). Results
have been expressed in units per g of colonic mucosa.
2.9. Histological Examination of the Colon. Samples of
the colon were fixed in 10% buffered formaldehyde and
embedded in paraffin. Paraffin sections were stained with
hematoxylin and eosin and examined by the pathologist
uninformed about treatment given. The histological grading
of colonic damage such as ulceration, inflammation, depth
of the lesion, and fibrosis was determined using a scale
previously presented by Vilaseca et al. [34].
2.10. Statistical Analysis. Results were presented as a mean
value± standard error (SEM). Statistical assessment was done
through one-way analysis of variance followed by Tukey’s
multiple comparison test using GraphPad Prism (GraphPad
Software, San Diego, CA, USA). Differences were considered
to be statistically significant if 𝑃 was less than 0.05.
3. Results
In control group of animals, mean daily water intake was
18.6 ± 1.6mL (Figure 1). Intraperitoneal administration of
ghrelin at the dose of 8 nmol/kg/dose resulted in a slight
increase inwater intake in animalswateredwith tapwater, but
this effect was statistically insignificant. Also, administration
of DSS in drinking water was without a significant effect on
the daily intake of water. In the group of animals receiving in
drinking water 5% solution of DSS and treated with ghrelin,
daily intake of water reached was the greatest value, but also
this effect was not statistically significant (Figure 1).
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Figure 1: Influence of dextran sodium sulfate (DSS) administered in
drinking water and saline (NaCl) or ghrelin given intraperitoneally
at the dose of 8 nmol/kg/dose (G8) on daily water intake. Mean ±
SEM.𝑁 = 10 animals in each group.
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Figure 2: Influence of dextran sodium sulfate (DSS) administered in
drinking water and saline (NaCl) or ghrelin given intraperitoneally
at the dose of 8 nmol/kg/dose (G8) on daily body weight gain. Mean
± SEM. 𝑁 = 10 animals in each group. a𝑃 < 0.05 compared to
control (C); b𝑃 < 0.05 compared to DSS plus NaCl.
In control animals receiving tap water and treated
intraperitoneally with saline, a mean daily body weight gain
within five days of observation was 3.1 ± 0.1 g (Figure 2).
Administration of ghrelin led to statistically significant
increase by 41% in that parameter. Addition of DSS to
drinking water resulted in a decrease in body weight in
comparison to initial body weight. Administration of ghrelin
significantly reversed the bodyweight loss in animals watered
with 5% solution ofDSS, leading to a bodyweight gain similar
to that observed in the control animals (Figure 2).
No macroscopic damage of the colon was observed in all
rats used in the present study. Also, no damage was observed
in microscopic morphological features of the colon obtained
from control rats or rats treatedwith ghrelin andwateredwith
tap water (Table 1, Figures 3 and 4). In the case of animals
wateredwith aqueous solution of DSS and treatedwith saline,
microscopic examination revealed the presence of small or
large erosion extending into the submucosa or muscularis
propria. Also moderate or severe inflammatory infiltrations
and mild fibrosis were observed (Table 1, Figure 5). In most
cases of animals watered with aqueous solution of DSS,
administration of ghrelin prevented the formation of colonic
lesions but failed to affect inflammatory infiltration (Table 1,
Figure 6).
In the animals from the control group, the rate of DNA
synthesis in colonic mucosa reached a value of 41.5 ±
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Table 1: Influence of dextran sodium sulfate (DSS) administered in drinking water and saline (NaCl) or ghrelin given intraperitoneally at the
dose of 8 nmol/kg/dose on morphological signs of colonic damage.
Morphological changes
Size of lesions Inflammatory infiltration Depth of lesions Fibrosis
(0–2) (0–3) (0–3) (0–3)
Control
Scoring observed in individual animals 0, 0, 0, 0, 0 0, 0, 0, 0, 0 0, 0, 0, 0, 0 0, 0, 0, 0, 01, 0, 0, 0, 0 0, 0, 0, 0, 0 1, 0, 0, 0, 0 0, 0, 0, 0, 0
The predominant grading 0 0 0 0
Ghrelin
Scoring observed in individual animals 0, 0, 0, 0, 0 0, 0, 0, 0, 0 0, 0, 0, 0, 0 0, 0, 0, 0, 00, 0, 0, 0, 0 0, 0, 0, 0, 0 0, 0, 0, 0, 0 0, 0, 0, 0, 0
The predominant grading 0 0 0 0
DSS
Scoring observed in individual animals 1, 1, 2, 1, 2 2, 2, 3, 2, 3 1, 1, 2, 1, 1 0, 1, 2, 1, 11, 2, 2, 2, 2 2, 3, 3, 2, 2 1, 1, 1, 1, 1 1, 1, 1, 1, 1
The predominant grading 1-2 2-3 1 1
DSS + Ghrelin
Scoring observed in individual animals 0, 1, 0, 0, 0 2, 3, 2, 2, 3 0, 1, 0, 0, 0 0, 0, 0, 0, 01, 0, 1, 0, 0 1, 2, 3, 2, 3 1, 0, 1, 0, 0 0, 0, 1, 0, 0
The predominant grading 0 2-3 0 0
Figure 3: A typical microscopic image of colonic mucosa taken
from the control animals watered with tap water and treated
intraperitoneally with saline (NaCl). Hematoxylin-eosin counter-
stain. Original magnification 200x.
1.3 dpm/𝜇g DNA (Figure 7). In animals watered with tap
water, administration of ghrelin resulted in an increase
in mucosal DNA synthesis, but this effect was statistically
insignificant. Watering with DSS significantly reduced DNA
synthesis by 22% in comparison to a level observed in control
animals. Administration of ghrelin partly but significantly
reversed the DSS-evoked reduction in DNA synthesis in
colonic mucosa (Figure 7).
Administration of ghrelin failed to affect mucosal blood
flow in the colon in animalswateredwith tapwater (Figure 8).
Induction of colitis by administration of DSS led to a
statistically significant decrease in colonic mucosal blood
flow by about 28%, when compared to a value observed
in animals from control group (Figure 8). Administration
of ghrelin partly, but significantly, reversed the DSS-evoked
decrease in mucosal blood flow in the colon.
The concentration of proinflammatory interleukin-1𝛽
(IL-1𝛽) in colonic mucosa in control animals was 0.50 ±
0.03 ng/g of tissue (Figure 9). Administration of ghrelin was
Figure 4: A typical microscopic image of colonic mucosa taken
from the animals watered with tap water and treated intraperi-
toneally with ghrelin. Hematoxylin-eosin counterstain. Original
magnification 400x.
without significant effect on IL-1𝛽 concentration in colonic
mucosa in animalswateredwith tapwater. Induction of colitis
by wateringwithDSS solution led to a 3-fold increase in IL-1𝛽
concentration in colonic mucosa. Administration of ghrelin
partly, but significantly, reversed the DSS-evoked increase in
that parameter (Figure 9).
Administration of ghrelin was without significant effect
on the level of malondialdehyde (MDA) in colonic mucosa
in animals watered with tap water (Figure 10). Addition of
DSS to water resulted in almost a 2-fold increase in the
concentration of MDA in the colonic mucosa in comparison
to concentration observed in the control animals. In rats
watered withDSS solution, administration of ghrelin resulted
in a statistically significant reduction in the concentration of
MDA in the colonic mucosa (Figure 10).
In control saline-treated animals, superoxide dismutase
(SOD) activity in colonicmucosawas low and reached a value
of 357.2 ± 19.8U/g of tissue (Figure 11). Administration of
ghrelin failed to affect SOD activity in colonic mucosa in
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Figure 5: A typical microscopic image of colonic mucosa taken
from the animals watered with DSS solution and treated intraperi-
toneallywith saline.Hematoxylin-eosin counterstain.Originalmag-
nification 100x.
Figure 6: A typical microscopic image of colonic mucosa taken
from the animals watered with DSS solution and treated intraperi-
toneally with ghrelin. Hematoxylin-eosin counterstain. Original
magnification 200x.
rats without induction of colitis. Induction of colitis by DSS
solution resulted in a significant decrease in SOD activity
in colonic mucosa. In those rats, administration of ghrelin
partly, but significantly, reversed the DSS-evoked decrease in
mucosal SOD activity in the colon (Figure 11).
4. Discussion
Our present study has provided several important obser-
vations regarding the influence of exogenous ghrelin on
the integrity of the colonic mucosa. We have found that
treatment with ghrelin exhibits protective effect on the colon.
Ghrelin given during administration of DSS inhibited the
development of DSS-induced colitis. This effect was man-
ifested as an improvement of colonic morphology in the
microscopic examination, a partial reversion of the colitis-
evoked reduction in mucosal cell vitality and an increase
in mucosal blood flow, as well as a decrease in biochemical
indices of inflammation.
DNA synthesis, measured by incorporation of labeled
thymidine into DNA, is an index of cell vitality and cell pro-
liferation [32]. Our present study has shown that induction of
colitis is associatedwith a decrease inmucosal DNA synthesis
in the colon.The rate ofmucosal DNA synthesis was inversely
proportional to the grade of colonic damage. In rats without
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Figure 7: Influence of dextran sodium sulfate (DSS) administered in
drinking water and saline (NaCl) or ghrelin given intraperitoneally
at the dose of 8 nmol/kg/dose (G8) on DNA synthesis in colonic
mucosa. Mean ± SEM. 𝑁 = 10 animals in each group. a𝑃 < 0.05
compared to control (C); b𝑃 < 0.05 compared to DSS plus NaCl.
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Figure 8: Influence of dextran sodium sulfate (DSS) administered in
drinking water and saline (NaCl) or ghrelin given intraperitoneally
at the dose of 8 nmol/kg/dose (G8) on mucosal blood flow in the
colon. Mean ± SEM. 𝑁 = 10 animals in each group. a𝑃 < 0.05
compared to control (C); b𝑃 < 0.05 compared to DSS plus NaCl.
induction of colitis, administration of ghrelin was without a
significant influence on DNA synthesis in colonic mucosa.
On the other hand, administration of ghrelin in animals
watered with DSS solution caused a considerable reversal of
DSS-evoked decrease in DNA synthesis in the colon. These
findings indicate that protective effect of ghrelin in the colon
is related, at least in part, to an increase in vitality of cells in
colonic mucosa.
The maintenance of normal blood flow through micro-
circulation plays a fundamental role in the protection and
healing of mucosa in the gut [35–38]. Previous studies
have shown that exposure of gastric mucosa to potentially
damaging factors results in little or no damage, as long as
an adequate blood flow is sustained. On the other hand,
a decrease in mucosal blood flow increases the severity
and extension of gastric lesions [35]. The importance of
appropriate blood flow in maintaining mucosal integrity
and healing of mucosa damage has been also found in
other parts of the digestive tract system such as the oral
cavity [19], esophagus [36], duodenum [37], and colon [38].
Findings of our present study are in harmony with those
data. Administration of ghrelin during colitis induction by
DSS led to a significant restitution of appropriate blood
flood through colonic microcirculation. This observation
6 BioMed Research International
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Figure 9: Influence of dextran sodium sulfate (DSS) administered in
drinking water and saline (NaCl) or ghrelin given intraperitoneally
at the dose of 8 nmol/kg/dose (G8) on interleukin-1𝛽 concentration
in colonic mucosa. Mean ± SEM. 𝑁 = 10 animals in each group.
a𝑃 < 0.05 compared to control (C); b𝑃 < 0.05 compared to DSS plus
NaCl.
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Figure 10: Influence of dextran sodium sulfate (DSS) administered
in drinking water and saline (NaCl) or ghrelin given intraperi-
toneally at the dose of 8 nmol/kg/dose (G8) on malondialdehyde
concentration in colonic mucosa Mean ± SEM. 𝑁 = 10 animals in
each group. a𝑃 < 0.05 compared to control (C); b𝑃 < 0.05 compared
to DSS plus NaCl.
indicates that ghrelin’s protective effect on colonic mucosa
is connected with its influence on mucosal blood flow.
A question remains, however, whether the ghrelin-evoked
improvement of blood flood through colonic mucosa in rats
with colitis is a mechanism or a result of ghrelin’s protective
effect in the colon.
A next interesting discovery of our present study con-
cerned the influence of DSS and ghrelin administration on
biochemical indices of inflammation and oxidative stress.
Interleukin-1𝛽 (IL-1𝛽) plays a crucial role in the induction of
local inflammation and systemic acute phase response. Also,
it is responsible for the release of subsequent proinflamma-
tory cytokines in the biochemical cascade of inflammation
[39, 40]. Our present study has shown that induction of
colitis byDSS leads to a damage and inflammatory infiltration
of colonic mucosa and increases mucosal concentration of
IL-1𝛽, whereas administration of ghrelin decreases mucosal
concentration of IL-1𝛽 in rats watered with DSS solution.
These data indicate that ghrelin reduces a local inflammatory
response in colitis induced by DSS and this effect seems to
be one of the mechanisms involved in the ghrelin-evoked
protective effect in the colon.
Tissue concentration of malondialdehyde (MDA) is a
biological marker of oxidative stress [41], whereas superoxide
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Figure 11: Influence of dextran sodium sulfate (DSS) administered
in drinking water and saline (NaCl) or ghrelin given intraperi-
toneally at the dose of 8 nmol/kg/dose (G8) on superoxide dismutase
activity in colonic mucosa. Mean ± SEM. 𝑁 = 10 animals in each
group. a𝑃 < 0.05 compared to control (C); b𝑃 < 0.05 compared to
DSS plus NaCl.
dismutase (SOD), catalase, and glutathione peroxidase are
the main enzymes responsible for reactive oxygen species
(ROS) neutralization [42]. Involvement of ROS has been
shown, among others, in the pathogenesis of gastric [42, 43]
and colonic damage [44]. In our present study, administra-
tion of ghrelin failed to affect MDA concentration or SOD
activity in colonic mucosa in rats watered with tap water.
Induction of colitis increased the concentration of MDA, a
lipid peroxidation product, in colonic mucosa and this effect
was associated with a reduction in mucosal SOD activity,
leading to additional disruption of redox balance. On the
other hand, administration of ghrelin partly, but signifi-
cantly, reversed the DSS-induced increase in mucosal MDA
concentration and this effect was associated with partial
restoration of mucosal activity of SOD. These observations
indicate that treatment with ghrelin reduces the colitis-
induced oxidative stress in colonic mucosa and improves the
antioxidant defense in this inflammation.
Ghrelin stimulates growth hormone and IGF-1 secretion
and as promitotic agent can be potentially directly or indi-
rectly involved in carcinogenesis [45, 46]. The stomach is a
main source of circulating ghrelin, but this peptide is also
widely expressed in other tissues in normal and malignant
conditions [6–8, 46]. Several endocrine and nonendocrine
tumors, such as pituitary adenomas, thyroid tumors, carci-
noids, lung and breast cancer, and colorectal cancer as well
as gastric and pancreatic adenocarcinoma express ghrelin
and ghrelin’s receptor at both mRNA and protein level [46].
However, the influence of ghrelin on cancer risk is unclear.
There are some early studies showing that ghrelin increases
proliferation and invasiveness of pancreatic adenocarcinoma
[47], hepatoma [48], and adrenocortical tumor cells [49]. On
the other hand, numerous recent clinical and experimental
studies [8, 50, 51], including our present data, indicate that
ghrelin exhibits anti-inflammatory effect and plays a role
in protecting against cancer-related inflammation [52] and
inflammation-associated carcinogenesis [53]. For this reason,
clinical observations also indicate that low levels of ghrelin
are associated with an increased risk of esophageal, gastric,
and esophagogastric junctional adenocarcinoma [54, 55].
BioMed Research International 7
Similar antitumor effect of ghrelin has been detected in breast
cancer. Patients with breast cancer expressing ghrelin have a
2.5–3-fold lower risk for recurrence or breast cancer death
than those lacking ghrelin expression [56]. Moreover, recent
clinical studies indicate that ghrelin can be useful in the
postoperative support and treatment of anorexia-cachexia
syndrome of cancer patients [57, 58]. Treatment with ghrelin
for cancer-related cachexia improves the patients’ general
conditions and their quality of life [52, 57, 58].
Finally, we conclude that administration of ghrelin pro-
tects the large bowel against the development of DSS-induced
colitis. This observation suggests that treatment with ghrelin
can be useful in maintaining the IBD patients in remission.
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